François Meyer

François Meyer

Auto-generated profile, based on publicly available information

François Meyer


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Das Gesundheitswesen
Verified
Journal Article
Closed access
MPM. S. Pfannkuche
M. S. Pfannkuche
FHFalk Hoffmann
Falk Hoffmann
FMF. Meyer
F. Meyer
GGG. Glaeske
G. Glaeske
Hintergrund: Gesundheitspolitische Diskussionen verfolgen häufig das Ziel, die Effizienz in der Arzneimittelversorgung zu steigern. Hierfür werden Einsparpotenziale quantifiziert, die auf der Grundlage von GKV-Routinedaten basieren. Diese Arbeit versteht sich als Beitrag zur methodischen Diskussion zur Ermittlung solcher Einsparpotenziale. Methodik: Grundlage der Analyse waren Routinedaten der Gmünder ErsatzKasse (GEK) aus dem Jahr 2005. Es werden vier verschiedene Methoden zur Berechnung von Effizienzreserven im Generikamarkt anhand des Wirkstoffs Omeprazol vorgestellt. Ergebnisse: Je nach verwendeter Methodik sind verschiedene Annahmen und Abstraktionen sowie unterschiedliche Informationen erforderlich. Die ermittelten Effizienzreserven differieren in unserem Beispiel zwischen 741 Tsd. Euro und 165 Tsd. Euro (entspricht ca. 80%). Gemessen an den Gesamtausgaben für den Wirkstoff Omeprazol resultieren je nach verwendeter Methodik Einsparpotenziale zwischen 2,9 und 13,1%. Schlussfolgerungen: Die Höhe und auch die Relevanz theoretischer Einsparpotenziale hängen sehr stark von den zugrunde liegenden Annahmen und der verwendeten Methodik ab. Im Idealfall sollten die Berechnungen auf der Ebene des einzelnen Arzneimittels unter Berücksichtigung der Arzneimittelpreise zum Verordnungszeitpunkt erfolgen. Eine ausführliche Beschreibung der Methodik ist Vorraussetzung für eine adäquate Beurteilung der Ergebnisse. Background: Discussions in health-care policy frequently pursue a raising efficiency in drug utilisation. Therefore saving potentials are quantified based on health insurance company claims data. This article is a contribution to methodical discussions about the determination of saving potentials in drug utilisation. Methods: Based on claims data from the health insurance company Gmuender ErsatzKasse (GEK) of 2005, four different methods to calculate efficiency potentials in the generic drug market are presented. The different effects are illustrated for the example of Omeprazol. Results: Depending on the used methods, different estimates, abstractions and varied information are required. In the given example the identified increase in efficiency varies between 741,000 Euro and 165,000 Euro (80%). According to the used method, saving potentials range between 2.9% and 13.1% as measured by the total expenditure for Omeprazol. Conclusion: The amount and the pertinence of saving potentials in theory are highly dependent on underlying assumptions and used methods. Calculations on the level of several drugs should, in the best case, occur at the time of prescription under consideration of drug prices. A detailed methods description is required for an appropriate outcome evaluation.

23 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
EEErsin Ersözlü
Ersin Ersözlü
OAOrkan Arslan
Orkan Arslan
FMFrançois Meyer
François Meyer
LPLukas Preis
Lukas Preis
JHJulian Hellmann-Regen
Julian Hellmann-Regen
BackgroundCerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer’s disease neuropathologic change (ADNC) and is increasingly relevant in the anti-amyloid therapy era. Our study aims to examine associations between neuropathological CAA status, MRI-defined probable CAA (pCAA), and longitudinal cognitive decline.MethodsThirty-six Alzheimer’s Disease Neuroimaging Initiative participants with post-mortem neuropathological assessment and at least 2 suitable in vivo Magnetic resonance imaging (MRI) scans were included for ratings according to the Boston criteria v2.0. Participants were grouped as ADNC−/CAA−, ADNC+/CAA−, or ADNC(+)/CAA+, according to the binarized status of moderate-to-severe disease. Baseline clinical, biomarker, genetic, vascular, and anti-amyloid therapy eligibility measures were compared across groups. Logistic regression assessed associations with neuropathological CAA diagnosis. Cox regression models and Kaplan-Meier curves were used to evaluate the occurrence of pCAA. Linear mixed-effects models tested cognitive trajectories.ResultsParticipants with pCAA had more advanced CAA and ADNC severity, higher Apolipoprotein (APOE) ε4 frequency, and lower MRI-based eligibility for anti-amyloid therapy. The logistic model predicting neuropathological CAA diagnosis was significant, although no individual predictor reached significance. APOE ε4 carrier status predicted pCAA occurrence and was driven by groups of participants with ADNC and comorbid CAA at autopsy. Baseline pCAA was associated with faster cognitive decline in memory, executive function, and language.ConclusionBoston criteria v2.0 MRI-defined pCAA may capture a clinically meaningful cerebrovascular phenotype in AD, characterized by more frequent concomitant CAA pathology and an enhanced risk of cognitive decline. These hypothesis-generating findings warrant validation in larger longitudinal cohorts.